Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anavex Life Sciences

9.48
-0.0900-0.94%
Post-market: 9.31-0.1730-1.82%19:53 EDT
Volume:2.82M
Turnover:26.72M
Market Cap:809.33M
PE:-17.05
High:9.78
Open:9.66
Low:9.28
Close:9.57
Loading ...

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Apr

Anavex announces results from Phase IIb/III open-label extension trial

TIPRANKS
·
06 Apr

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results From Phase Iib/Iii Open-Label Extension Trial in Early Alzheimer’s Disease

THOMSON REUTERS
·
05 Apr

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

GlobeNewswire
·
05 Apr

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
31 Mar

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar

Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus

Zacks
·
17 Mar

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL) and Applied DNA Sciences (APDN)

TIPRANKS
·
28 Feb

When Will Anavex Life Sciences Corp. (NASDAQ:AVXL) Breakeven?

Simply Wall St.
·
26 Feb

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

GlobeNewswire
·
24 Feb

Stock Track | Anavex Life Sciences Soars 5.16% on Analyst's Buy Rating and European Growth Outlook

Stock Track
·
18 Feb

Buy Rating for Anavex Life Sciences Due to Solid Financials and European Market Potential

TIPRANKS
·
18 Feb

Anavex Life Sciences Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Feb

Stock Track | Anavex Life Sciences Soars 5.55% Pre-Market on Upbeat Q1 Results, Patent Win for Alzheimer's Drug

Stock Track
·
12 Feb

Anavex Life Sciences Q1 2025 GAAP EPS $(0.14) Beats $(0.19) Estimate, Cash And Cash Equivalents Of $120.8M At December 31, 2024, The Company Anticipates At Current Cash Utilization Rates And Ranges, A Runway Of Approximately 4 Years

Benzinga
·
12 Feb

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Associated Press Finance
·
12 Feb

Anavex Life Sciences Corp - Q1 Net Loss $12.1 Million, $0.14 per Share

THOMSON REUTERS
·
12 Feb

Anavex Life Sciences Corp expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
10 Feb